Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Circulation: Journal of the American Heart Association

• Publication date

  2001-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.103.2.314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone.

  2000cited by this paper
• Monocrotaline-Induced Pulmonary Hypertension Mediated Vasodilation in − Receptor Blockade Improves Nitric

  1998cited by this paper
• L-NAME potentiates endothelin-stimulated thromboxane release from guinea pig lung.

  1998cited by this paper
• Blocking of the endothelin system: the development of receptor antagonists.

  1998cited by this paper
• EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension.

  1998cited by this paper
• Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.

  1997cited by this paper
• Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure.

  1997cited by this paper
• ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit.

  1997cited by this paper
• The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.

  1997cited by this paper
• Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats.

  1996cited by this paper
• Human pulmonary circulation is an important site for both clearance and production of endothelin-1.

  1996cited by this paper
• Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors.

  1996cited by this paper
• Effect of stretch on contraction and the Ca2+ transient in ferret ventricular muscles during hypoxia and acidosis.

  1995cited by this paper
• ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat.

  1995cited by this paper
• Contraction to endothelin-1 in pulmonary arteries from endotoxin-treated rats is modulated by endothelium.

  1995cited by this paper
• Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.

  1995cited by this paper
• Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs.

  1995cited by this paper
• Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension.

  1995cited by this paper
• Forearm Vasoconstriction to Endothelin‐1 Is Mediated by ETA and ETB Receptors In Vivo in Humans

  1995cited by this paper
• EndothelinB Receptor‐Mediated Contraction of Human and Rat Pulmonary Resistance Arteries and the Effect of Pulmonary Hypertension on Endothelin Responses in the Rat

  1995cited by this paper
• Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis.

  1993cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.

  1993cited by this paper
• BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells.

  1993cited by this paper
• Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects : evidence for increased production of endothelin in pulmonary circulation

  1992cited by this paper
• Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure

  1992cited by this paper
• Mechanism of endothelin-1-induced pulmonary vasoconstriction.

  1991cited by this paper
• Plasma Endothelin Concentrations in Patients With Pulmonary Hypertension Associated With Congenital Heart Defects: Evidence for Increased Production of Endothelin in Pulmonary Circulation

  1991cited by this paper
• Cloning and expression of a cDNA encoding an endothelin receptor

  1990cited by this paper
• Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

  1988cited by this paper

• Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

  2023cites this paper
• AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling

  2021cites this paper
• Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients.

  2019cites this paper
• Therapeutic Monoclonal Antibody Antagonizing Endothelin Receptor A for Pulmonary Arterial Hypertension

  2019cites this paper
• The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension

  2018cites this paper
• Animal models of pulmonary arterial hypertension: A systematic review and meta‐analysis of data from 6126 animals

  2017cites this paper
• Role of cardiac inflammation in right ventricular failure

  2017cites this paper
• hypoxia-induced endothelin signaling in vitro and in vivo ligand rosiglitazone attenuates γ

  2016cites this paper
• Peroxisome Proliferator-Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling.

  2016cites this paper
• Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial

  2016cites this paper
• Optimized EPA/DHA 6/1 formulation prevents Angiotensin-II induced hypertension and endothelial dysfunction in rats

  2016cites this paper
• Bicalutamide causes heart failure in an elderly patient with prostate cancer

  2016cites this paper
• Rôle de SIRT1 et de la biogenèse mitochondriale dans la prolifération des cellules du muscle lisse de l'artère pulmonaire

  2015cites this paper
• Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors

  2015cites this paper
• Development of macitentan for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Pathophysiology of Infantile Pulmonary Arterial Hypertension Induced by Monocrotaline

  2015cites this paper
• Adaptive capacity of the right ventricle: why does it fail?

  2015cites this paper
• Pulmonary hypertension after prolonged hypoxic exposure in mice with a congenital deficiency of Cyp2j.

  2015cites this paper
• Ethyl Pyruvate Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

  2014cites this paper
• Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats

  2014cites this paper
• Apoptosis and Inflammation Associated Gene Expressions in Monocrotaline-Induced Pulmonary Hypertensive Rats after Bosentan Treatment

  2014cites this paper
• Transfection of human hepatocyte growth factor gene inhibits advancing pulmonary arterial hypertension induced by shunt flow in a rabbit model.

  2013cites this paper
• Antagonistas de los receptores de la endotelina para la hipertensión arterial pulmonar

  2013cites this paper
• Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.

  2013cites this paper
• Endothelin receptor antagonists.

  2013cites this paper
• Role of Rho-kinase and its inhibitors in pulmonary hypertension.

  2013cites this paper
• Development of strategies for vascular damage repair in Pulmonary Arterial Hypertension

  2013cites this paper
• Effect of Small Hairpin RNA Targeting Endothelin-Converting Enzyme-1 in Monocrotaline-Induced Pulmonary Hypertensive Rats

  2012cites this paper
• Pulmonary Arterial Hypertension: Classification and Therapy With a Focus on Prostaglandin Analogs

  2012cites this paper
• Improved Cell Survival and Paracrine Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Therapeutic Potential for Pulmonary Arterial Hypertension

  2012cites this paper
• Pathophysiological roles of endothelin receptors in cardiovascular diseases.

  2012cites this paper
• Doppler flow spectra of the superior vena cava in a rat model of chronic pulmonary hypertension

  2011cites this paper
• The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.

  2011cites this paper
• Fisiopatologia da Hipertensão Arterial Pulmonar Infantil Induzida pela Monocrotalina

  2011cites this paper
• Effects of simvastatin on pulmonary C-fiber sensitivity in rats with monocrotaline-induced pulmonary hypertension.

  2011cites this paper
• Role of endothelin in the cardiovascular system.

  2011cites this paper
• Animal Models of Pulmonary Hypertension

  2011cites this paper
• Alteracions vasculars pulmonars induïdes per l’exposició a fum de tabac en un model animal de MPOC

  2011cites this paper
• The effects of statins on hypoxia-induced proliferation and cell signalling pathways in pulmonary artery fibroblasts

  2010cites this paper
• Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.

  2010cites this paper
• Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat

  2010influential citation
• At the heart of tissue: endothelin system and end-organ damage.

  2010cites this paper
• Pharmacotherapeutic management of pulmonary arterial hypertension.

  2010cites this paper
• Avaliação da expressão génica e vias subcelulares neuroendócrinas e metabólicas em modelos experimentais de hipertensão pulmonar

  2010cites this paper
• Endothelin receptor antagonists in preclinical models of pulmonary hypertension

  2009cites this paper
• Molecular mechanisms of pulmonary hypertension.

  2009cites this paper
• Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.

  2009cites this paper
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

  2009cites this paper
• Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism.

  2009cites this paper
• Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

  2009cites this paper
• Effects of selective and unselective endothelin‐receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension

  2008cites this paper
• Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension

  2008cites this paper
• Ambrisentan for the treatment of pulmonary arterial hypertension

  2008cites this paper
• Myocardial effects of endothelin-1.

  2008cites this paper
• Inhalation of endothelin receptor blockers in pulmonary hypertension.

  2008cites this paper
• Rescue of Pulmonary Hypertension with an Oral Sulfonamide Antibiotic Sulfisoxazole by Endothelin Receptor Antagonistic Actions

  2008cites this paper
• Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

  2008cites this paper
• Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension

  2008cites this paper
• New Directions in Pulmonary Hypertension Therapy

  2008cites this paper
• Inibidores da enzima de conversão da endotelina e sua aplicação na patologia cardiovascular.

  2008cites this paper
• Pathophysiology of Pulmonary Arterial Hypertension

  2007cites this paper
• Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

  2007cites this paper
• Dual endothelin receptor antagonism: setting standards in PAH

  2007cites this paper
• Sitaxsentan for the Prevention of Experimental Shunt-Induced Pulmonary Hypertension

  2007cites this paper
• Modèles animaux d'hypertension artérielle pulmonaire.

  2007cites this paper
• Expert opinion on available options treating pulmonary arterial hypertension

  2007cites this paper
• Endothelin: setting the scene in PAH

  2007cites this paper
• Survival in patients with pulmonary arterial hypertension treated with first‐line bosentan

  2006cites this paper
• Endothelin receptor antagonists.

  2006cites this paper
• Bosentan, Sildenafil, and Their Combination in the Monocrotaline Model of Pulmonary Hypertension in Rats

  2006cites this paper
• Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure

  2006cites this paper
• Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension

  2006cites this paper
• Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.

  2006cites this paper
• Influence of BQ 123 on synthesis of collagens type I and III in the lungs of rats with left to right shunt pulmonary hypertension

  2006cites this paper
• How valid are animal models to evaluate treatments for pulmonary hypertension?

  2006cites this paper
• Endothelin receptors as drug targets in chronic cardiovascular diseases: the rationale for dual antagonism

  2006cites this paper
• Recent advances in the treatment of pulmonary hypertension.

  2005cites this paper
• Gene Therapy with Hepatocyte Growth Factor for Angiogenesis in Severe Pulmonary Vascular Disease

  2005cites this paper
• Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine

  2005cites this paper
• The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.

  2004cites this paper
• Roles of Endothelin ETA and ETB Receptors in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension

  2004influential citation
• Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats.

  2004cites this paper
• The endothelin system in pulmonary arterial hypertension.

  2004cites this paper
• Role of Endothelin-1 and Thromboxane A2 in the Pulmonary Hypertension Induced by Heparin–Protamine Interaction in Anesthetized Dogs

  2004cites this paper
• Hepatocyte Growth Factor Suppresses Vascular Medial Hyperplasia and Matrix Accumulation in Advanced Pulmonary Hypertension of Rats

  2004cites this paper
• Pulmonary arterial hypertension: cardiovascular effects of pharmacological intervention

  2003cites this paper
• Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long‐term benefit?

  2003cites this paper
• The endothelin system in pulmonary hypertension.

  2003cites this paper
• Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease

  2003cites this paper
• Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs.

  2003cites this paper
• The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb.

  2002cites this paper
• Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.

  2002cites this paper
• Targeting mediators of vascular injury in scleroderma.

  2002cites this paper
• ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

  2002cites this paper
• Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension.

  2002cites this paper
• Endothelin-receptor antagonists in pulmonary hypertension.

  2001cites this paper
• Endothelins and pulmonary hypertension, what directions for the near future?

  2001cites this paper